Clinical Trial Update: ACE393-103 Vaccination Challenge Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the ACE393-103 vaccination challenge study evaluating protection against Campylobacteriosis; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Campylobacteriosis

Drugs mentioned

• ACE393-103

Snippet

Sponsor: TD Vaccines A/S | Conditions: Campylobacter Infection | Phase 2 | Status: UNKNOWN